Search Videos and More

Showing 1 - 12 of 423 results

Previous| 1 | 2 | 3 ...36 |Next


Dana-Farber Research News 07.01.2025 News

Dana-Farber Research News 07.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.
Novel Cancer Screening Test for Veterans Now Being Offered at Dana-Farber Cancer Institute News

Novel Cancer Screening Test for Veterans Now Being Offered at Dana-Farber Cancer Institute

During their time of service, members of the U.S. Armed Forces face considerable risks while fulfilling their mission and protecting the country. However, a less visible risk to the wellbeing of U.S. military members and veterans is on the rise.
Dana-Farber Research News 06.15.2025 News

Dana-Farber Research News 06.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 through May 31.
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer News

FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
Double Negative in Cells Could Undermine PARP Inhibitors News

Double Negative in Cells Could Undermine PARP Inhibitors

There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.  
Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer Document

Datopotamab Deruxtecan (Dato-DXd) in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer

Our Breast Oncology Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer News

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) plus pertuzumab, nearly doubled progression-free survival compared to the currently accepted standard treatment with taxane chemotherapy plus trastuzumab and pertuzumab (THP) for first-line therapy of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 
Dana-Farber Research News 06.01.2025 News

Dana-Farber Research News 06.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 through May 15.
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds News

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds News

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer News

ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the current standard treatment.
EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk News

EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk

Dana-Farber Cancer Institute investigators launch a first-of-its-kind study to use a novel blood test to identify people who have never used tobacco but are at a high risk of lung cancer and offer them complimentary lung cancer screening.

Showing 1 - 12 of 423 results

Previous| 1 | 2 | 3 ...36 |Next